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Abstract
Transcription factors play a critical role in regulating the gene expression programs 
that establish and maintain specific cell states in humans. Deregulation of these gene 
expression programs can lead to a broad range of diseases including cancer. SOX tran-
scription factors are a conserved group of transcriptional regulators that mediates DNA 
binding by a highly conserved high-mobility group (HMG) domain. Numerous evidence 
has recently demonstrated that SOX transcription factors critically control cell fate and 
differentiation in major developmental processes, and that their upregulation may be 
important for cancer progression. In this review, we discuss recent advances in our 
understanding of the role of SOX genes in cancer.
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1. Introduction
Cancer is caused by alterations in the control and activity of genes that in turn regulate cell growth 
and differentiation, leading to abnormal cell proliferation [1]. It is a multi-step process leading to 
profound metabolic and behavioral changes in a cell. The hallmarks of cancer include sustain-
ing proliferative signaling, evading growth suppressors, resisting cell death, enabling replica-
tive immortality, inducing angiogenesis, activating invasion and metastasis, genome instability, 
inflammation, reprogramming of energy metabolism and evading immune destruction [2]. Most 
human malignancies are caused by somatic alterations within the cancer genome either through 
gain-of-function mutations in proto-oncogenes or loss-of-function mutations in tumor suppres-
sor genes. Remarkable progress in cancer research has been made in the last 10 years. However, 
the detailed molecular mechanisms of cancer remain largely un-elucidated.
A transcription factor (TF) might be defined as any molecule participating, alone or as part 
of a complex, in the binding to a gene’s enhancer response element or promoter, with the 
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ultimate outcome being the up- or down-regulation of expression of that gene [3]. TFs are 
key genes involved in the regulation of gene expression. The human genome encodes over 
2000 different TF-coding genes, many of which are expressed in a cell type-specific manner to 
coordinate gene expression programs underlying a vast array of cellular processes [4]. TFs are 
commonly deregulated in the pathogenesis of human cancer. For instance, TP53 and MYC, 
which encode the TFs p53 (tumor suppressor protein 53) and c-Myc respectively, are among 
the most frequently changed genes across all cancers [5, 6].
Sex determining region Y (SRY)-related high-mobility group (HMG) box (SOX) family com-
prises more than 20 members, which have been shown to involve in regulation of many 
biological processes such as embryonic development, cell-fate decision, lineage commit-
ment, determination and differentiation [7–9]. This transcription factor family is divided 
into 10 subgroups based on the level of amino acid conservation within the HMG box and 
the presence of other motifs. In this review, we discuss the current understanding on the 
association between SOX genes and cancer. We particularly emphasize the role of several 
representative SOX subgroup proteins (SOX2, SOX4, SOX9 and SOX11) in cancer initiation 
and development.
2. The biological functions of SOX gene family
SOX genes are part of a larger family of HMG proteins. SOX proteins bind similar DNA motifs 
[(A/T)(A/T)CAA(A/T)G] through their HMG domain, which is highly conserved among SOX 
gene family. Due to the low affinity between SOX proteins and DNA, cofactors are usually 
required to stabilize their interactions with DNA [9]. Based on the degree of conservation 
of their HMG-box and the presence of defined HMG-independent structural domains, SOX 
proteins are organized into 10 subfamilies: SOXA-SOXJ. For example, the SOXA group con-
sists only of SRY; SOXB group comprises of two subgroups (SOXB1 and SOXB2); SOXB1 
includes SOX1, SOX2, and SOX3, whereas SOXB2 proteins include SOX14 and SOX21; SOXC 
group includes SOX4, SOX11, and SOX12; SOXD group includes SOX5, SOX6, and SOX13; 
SOXE group includes SOX8, SOX9, and SOX10; and SOXF group includes SOX7, SOX17, and 
SOX18; SOXG (SOX15) and SOXH (SOX30) proteins are structurally related to SOXB1 and 
SOXD proteins, respectively [10–13]. Individual members within the same SOX group share 
similar biochemical properties and thus have overlapping biological functions. However, 
SOX proteins from different groups have distinct biological functions [9]. SOX gene family 
has been demonstrated to play important roles in various biological processes including, but 
not limited to development, tissue homeostasis and regeneration, reprogramming [9, 14–16].
In vertebrates, SOX genes are well known regulators of numerous developmental pro-
cesses. Accumulating evidences have shown that SOX proteins are co-expressed in vari-
ous developing tissues in an overlapping manner and show functional redundancy. The 
transcriptional activities of SOX proteins are regulated via three major pathways: (1) the 
expression levels of SOX proteins are regulated in specific cell types and tissues with pre-
cise timing (2) SOX proteins are regulated by posttranslational modification (3) the partners 
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of SOX proteins are regulated to not only influence the specific recognition of the bind-
ing sites of SOX-partner complexes on the target genes, but also determine transcription 
activities and significantly enhance the activation/repression potential. For instance, SOXB1 
and SOXB2 proteins are important for the development of the central nervous system and 
foregut system [17–19]. SOXD proteins are important for the development of cartilage tis-
sues. In mouse embryos, SOX5, SOX6, SOX9 and collagen II are co-expressed in all cartilagi-
nous sites at around 12.5 dpc. After 17.5 dpc, the chondrocytes become hypertrophic in the 
growth plate cartilages, the expression of above SOX genes are inhibited and disappear in 
the hypertrophic chondrocytes [20]. The expression patterns of SOXE genes are important 
for the development of reproductive system. SOX8, SOX9 and SOX10 are expressed in the 
overlapping temporal and spatial expression patterns during gonads development, indicat-
ing the overlapping roles of these genes in mammalian sex determination and subsequent 
male sexual development [21, 22]. The members of SOXF group play important roles in the 
development of cardio-vascular system and extraembryonic endoderm. SOX7 and SOX17 
are crucial endoderm lineage-determining regulators and are involved in the later stage of 
extraembryonic differentiation [23–25].
SOX2 is an important marker for stem and progenitor cell populations in many adult tissues. 
SOX2 positive cells have been detected in progenitors of various tissues such as adult ret-
ina, trachea, tongue epithelium, dermal papilla of the hair follicle, adult testes, forestomach, 
glandular stomach, anus, cervix, esophagus, lens and dental epithelium [26–30]. Conditional 
SOX2 deletion significantly influences cell proliferation. In trachea, SOX2 expression is 
required to sustain tissue homeostasis by controlling the number of proliferating epithe-
lial cells as well as the proportion of basal, ciliated and Clara cells [28]. However, whether 
SOX2 expression is required for homeostasis in other adult tissues needs further investiga-
tion. In addition to maintaining tissue homeostasis, SOX2 plays an important role for tissue 
regeneration and repair. For instance, the basal stem cells could repair the damaged tracheal 
epithelium in mice within 7–10 days. The number of basal stem cells was significantly lower 
in the trachea with SOX2-deficience. Therefore, the injured trachea was unable to undergo 
efficient tissue repair. SOX2 is also important for peripheral nerve regeneration. When there 
is injury, mature adult Schwann cells dedifferentiate to a progenitor cell-like state by re-
expressing Sox2 [31].
The expression of four transcription factors, Oct4/Sox2/cMyc/Klf4, was able to convert differ-
entiated cells to pluripotent cells [32]. SOX2 is indispensable for the success of this reprogram-
ming process. However, the biological function of SOX2 seems to be closely correlated with 
its levels. SOX2 overexpression can promote differentiation and reduce the reprogramming 
efficiency of neural progenitor cells. In addition to SOX2, SOX1 and SOX3, which are also 
members of SOXB1 family, can replace SOX2 during the reprogramming process. SOX15 or 
SOX18 was also able to generate the pluripotent cells but less efficient than SOXB1 family [33].
Many members of SOX gene family have been demonstrated to be closely correlated with 
tumorigenesis [34, 35]. Below, we discuss the involvement of several SOX genes that have 
been most extensively studied in human malignancies so far. Table 1 listed these SOX genes 
and their clinical relevance in cancers.
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3. SOX2 and cancer
The SOX2 gene is located on chromosome 3q26.3–q27, it belongs to the SOXB1 group and 
encodes for 317 amino acids [56, 57]. SOX2 is one of the key transcription factors for induced 
pluripotent stem cells establishment, stem cell maintenance, and lineage fate determinant. 
Deregulation of SOX2 has been associated with various diseases such as anophthalmia-esoph-
ageal-genital (AEG) syndrome and bilateral anaphthalmia/microphthalmia, anterior pitu-
itary hypoplasia, hypogonadotropic hypogonadism hypothalamic hamartoma, sensorineural 
hearing loss, and esophageal atresia [58, 59]. In addition to the above diseases, increasing evi-
dence has revealed there is a strong relationship between SOX2 and cancer. Cancer stem cells 
are key drivers of tumorigenesis and may be responsible for tumor initiation, growth and 
spawning metastases. SOX2-postive cancer stem cells were able to drive tumor initiation and 
therapy resistance in various types of cancers, indicating that it is a common phenomenon 
that SOX2 might mastermind the tumor initiating potential of cancer cells [60].
SOX2 silencing significantly suppresses the tumorigenicity of glioblastoma tumor-initi-
ating cells (TICs) [38]. Importantly, high levels of SOX2 have been associated with tumor 
aggressiveness and worse prognosis in glioblastoma, indicating targeting SOX2 might be an 
SOX genes Deregulation Potential clinical significance Reference
SOX2 Lung, esophagus and oral 
cancer↑
Promote tumor progression [36]
Melanoma↑ Enhance the self-renewal capacity of cancer 
stem cells
[37]
Glioblastoma ↑ Associated with tumor aggressiveness and 
worse prognosis
[38, 39]
Gastric cancer↓ Promote tumor progression [40]
SOX4 Oral cancer ↑ Promote tumor initiation and development [41, 42]
Prostate cancer↑ Associated with worse prognosis [43, 44]
Leukemia↑ Promote tumor progression [45]
Primary gallbladder carcinoma↓ Associated with worse prognosis [46]
SOX9 Papillary thyroid cancer↑ Promote tumor progression [47]
Breast cancer ↑ Associated with chemoresistance [48]
Gastric cancer ↑ Promote tumorigenesis [49]
Cervical carcinoma↓ Promote tumor progression [50]
SOX11 Breast cancer↑ Promote tumor progression [51]
Mantle cell lymphoma↑ Promote tumor progression [52–54]
Epithelial ovarian cancer↓ Associated with worse prognosis [55]
Gastric cancer↓ Associated with worse prognosis
Table 1. Deregulation of typical SOX genes and their clinical relevance in cancers.
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 effective strategy for the treatment of glioblastoma [39]. SOX2 is also amplified in squamous 
cell carcinomas of the lung, the esophagus, and the oral cavity. SOX2 amplification and SOX2 
protein overexpression might be responsible for the tumor initiation and progression in squa-
mous cell carcinomas derived from different organ sites [36]. SOX2 was found to be critical 
for maintaining the sphere-forming capacity of DU145 prostate cancer stem cells (PCSCs). 
It promoted the self-renewal of the PCSC population by regulating downstream of EGFR 
signaling [61]. Similarly, SOX2 was highly expressed in melanoma stem cells. SOX2 suppres-
sion remarkably inhibited self-renewal in melanoma spheres and in putative melanoma stem 
cells with high aldehyde dehydrogenase activity. On the contrary, SOX2 overexpression in 
melanoma cells enhanced their self-renewal in vitro. Animal models showed that SOX2 was 
critical for tumor initiation and continuous tumor growth. These data suggested that SOX2 
was an important factor for self-renewal and tumorigenicity of melanoma-initiating cells [37].
There are conflicting results regarding the role of SOX2 in gastric cancer. For instance, SOX2 
was dispensable for self-renewal of gastric stem cells. In addition, loss of SOX2 promoted tumor 
formation in Apc-deficient gastric cells in vivo and in vitro by inducing Tcf/Lef-dependent tran-
scription and upregulating intestinal metaplasia-associated genes, suggesting SOX2 acted as a 
tumor suppressor in gastric cancer [62]. In addition, the expression level of SOX2 expression 
was frequently downregulated in gastric cancers. Ectopic expression of SOX2 inhibited cell 
growth through cell-cycle arrest and apoptosis in gastric cells. Moreover, the gastric cancers 
with SOX2 methylation had a significantly worse survival than those without this methylation 
[40]. However, SOX2 was found to enhance the tumorigenicity and chemoresistance of cancer 
stem-like cells derived from gastric cancer, suggesting SOX2 plays an oncogenic role in gastric 
cancer [63]. SOX2 inhibition reduced cell proliferation and migration, promoted apoptosis 
and induced changes in cell cycle in vitro as well as suppressed the tumorigenic potential of 
gastric cancer cells in vivo [64]. The contradictory findings regarding the role of SOX2 in gas-
tric cancer further support the fact that the outcome of SOX2 activation is closely correlated 
with tumor origin and cellular context. Future experiments with lineage tracing and gain- 
and loss-of-function mouse models are required to clarify the role of SOX2 in gastric cancer. 
SOX2 is frequently regarded as an oncogene in lung SCCs, but previous studies indicated that 
higher SOX2 levels predicted favorable outcome in lung SCCs [65, 66]. The underlying reasons 
accounting for the contradictory role of SOX2 in lung SCCs warrant further exploration.
4. SOX4 and cancer
SOX4, one of group-C SOX genes, plays an important role in the regulation of transcription 
during developmental processes such as embryonic cardiac development, nervous system 
development, osteoblastic differentiation, and thymocyte development [67]. SOX4 gene 
is located on 6p22.3 and encodes a protein of 474 amino acids with three distinguishable 
domains: an HMG box, a glycine-rich region, and a serine-rich region. SOX4 is considered 
as one of the members of epithelial-mesenchymal transition (EMT)-transcriptional inducers. 
EMT is a key developmental program that is often activated during organismal development 
and the progression of epithelial tumors to metastatic cancers and may promote therapeutic 
resistance, indicating that SOX4 might be a potential therapeutic target for cancer treatment.
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Recently, multiple studies have reported altered expression of SOX4 in human cancers. Our 
group demonstrated that SOX4 was significantly upregulated when oral lichen planus (OLP) 
progressed to oral squamous cell carcinoma (OSCC). In addition, downregulation of SOX4 
suppressed the proliferation, migration and invasion of oral cancer cells. These findings sug-
gest that SOX4 might play a critical role in the progression of OLP to OSCC [41]. Similarly, the 
expression level of SOX4 was remarkably overexpressed in OSCC tissues compared to adjacent 
normal mucosa. Also SOX4 was important for maintaining the oncogenic phenotypes of oral 
cancer cells by promoting cell survival and increasing chemoradioresistance [68]. High SOX4 
expression levels were positively correlated with adverse clinicopathological parameters of 
OSCC, indicating that SOX4 might be significantly associated with poor prognosis of OSCC 
[42]. In addition to OSCC, SOX4 plays an oncogenic role in other malignancies. SOX4 was over-
expressed in prostate cancer (PCa) and higher SOX4 levels predicted unfavorable prognosis 
[43]. Upregulation of SOX4 in PCa was mechanistically induced by PTEN loss due to the acti-
vation of PI3K-AKT–mTOR signaling [44]. SOX4 was able to directly regulate the expression 
of the epigenetic modifier Ezh2 in breast cancer, indicating SOX4 might be indispensable for 
tumor progression [69]. SOX4 might combine with oncogenic Ras together to promote tumori-
genesis in vivo [70]. SOX4 was a direct target of C/EBPα and SOX4 suppression reduced the 
self-renewal of leukemic cells and restored their differentiation, indicating that SOX4 overex-
pression resulting from inactivation of C/EBPα promoted leukemia development [45].
However, it should be noted that SOX4 might also function as a tumor suppressor in tumori-
genesis. For instance, SOX4 was indispensable for p53 activation in response to DNA damage. 
In addition, SOX4 could stabilize p53 protein by inhibiting Mdm2-mediated p53 ubiquitina-
tion and degradation, suggesting that SOX4 might suppress the progression DNA damage 
response-associated cancer [71]. In primary gallbladder carcinoma (PGC), SOX4 upregulation 
was significantly associated with favorable clinical parameters. In addition, SOX4 overexpres-
sion predicted better survival [46]. The expression level of SOX4 was significantly reduced in 
metastatic melanoma compared with that in dysplastic nevi and primary melanoma. In addi-
tion, SOX4 suppression promoted the migration and invasion of melanoma cells in an NF-κB 
p50-dependent manner [72]. Taken together, these findings indicate that the concrete role of 
SOX4 is closely associated with tumor microenvironment and might be tissue specific.
5. SOX9 and cancer
The SOXE group comprises three members named SOX8, SOX9 and SOX10. SoxE proteins 
are important for the development of nervous system and neural crest progenitors. SOX9 
was first described as a candidate gene for campomelic dysplasia (CD), a genetic condition 
that affects the development of the skeleton and reproductive system [73]. SOX9 has been 
demonstrated to greatly contribute to the organogenesis and development of many tissue 
types, such as the stomach, pancreas, tooth and craniofacial tissues. In addition, SOX9 is also 
a master regulator of cartilage development. It is indispensable for roles in the chondrogenic 
lineage progression of mesenchymal stem cells [74].
Recent studies have reported that SOX9 is aberrantly expressed in several types of cancers. Higher 
expression levels of SOX9 are correlated with a poor prognosis in patients with Chordoma. In 
Gene Expression and Regulation in Mammalian Cells - Transcription From General Aspects312
addition, SOX9 downregulation suppressed the oncogenic behaviors of Chordoma cell in vitro, 
suggesting that SOX9 might function as an oncogene in Chordoma [75]. The expression of SOX9 
was upregulated in papillary thyroid cancer (PTC) tissues and cell lines. Downregulation of 
SOX9 inhibited the proliferation, colony formation, migration, invasion, as well as EMT phe-
notype of PTC cells. ERα–RUNX2 complex activated the SOX9 expression and promoted endo-
crine resistance and metastases [76]. In breast cancer, up-regulation of SOX9 expression was 
closely correlated with tamoxifen (TAM) resistance [77]. The SOX9 levels were significantly 
higher in osteosarcoma tissues compared with the adjacent normal tissues. However, CLDN8 
expression was significantly lower in osteosarcoma tissues. Knockdown of SOX9 inhibited the 
proliferation and migration but promoted the apoptosis of human osteosarcoma cell lines by 
downregulating CLDN8 [47]. FOXK2 was overexpressed in colorectal cancer tissues and asso-
ciated with poor prognosis. In fact, FOXK2 was shown to be transcriptionally activated by 
SOX9, suggesting that SOX9-FOXK2 axis plays a critical role in the development of colorectal 
cancer [48]. SOX9 upregulation was associated with Helicobacter pylori infection, elevated carci-
noembryonic antigen–related cell adhesion molecule 1 (CEACAM1) and gastrokine 1 (GKN1) 
inactivation. SOX9 knockdown suppressed the tumorigenic capacity of gastric cancer cells by 
inhibiting the downstream β-catenin signaling pathway [49]. Interestingly, SOX2 was expressed 
in highly proliferative but minimally invasive lung cancer cells; in contrast, cells with highly 
invasiveness capacity exhibited increased SOX9 expression but reduced SOX2 expression. The 
switch between SOX2 and SOX9 expression is epigenetically controlled and is important for 
determining cancer cell plasticity and metastatic progression [78]. Ectopic expression of SOX9 
enhanced growth, invasion, and angiogenesis, whereas silencing of endogenous SOX9 markedly 
impaired tumor growth in prostate cancer. High SOX9 levels drove tumorigenesis by reactivat-
ing the Wnt/β − catenin signaling in a subset of prostate cancer, indicating WNT inhibition might 
beneficial for the effective treatment of prostate cancer [79]. SOX9 was critical for maintaining 
proliferation, self-renewal, and tumorigenicity in liver cancer stem cells (CSCs), and SOX9 over-
expression was positively correlated with worse survival in HCC patients [80]. Although most 
studies showed that SOX9 played an oncogenic role in cancer development. Excopic expression 
of SOX9 was found to suppress cell growth, clonal capacity and colonosphere formation by 
inhibiting Wnt/ß-catenin signaling pathway and c-myc expression in colorectal cancer, suggest-
ing that SOX9 might be a tumor suppressor in colorectal cancer [81]. SOX9 expression was pro-
gressively decreased in cervical carcinoma in situ and especially in invasive cervical carcinoma, 
compared with normal cervix tissue. Lastly, SOX9 overexpression in cervical carcinoma cells 
inhibited cell growth in vitro and tumor formation in vivo, and vice versa [50].
6. SOX11 and cancer
Similar to SOX4, SOX11 is also a transcriptional activator that falls in the subgroup C. The 
Sox11 gene is mapped at chromosome 2p25.3 and the human SOX11 protein has 441 amino 
acids and 46.7 kDa molecular weight. It contains two functional domains: a HMG box 
DNA-binding domain and a transactivation domain [82]. SOX11 plays an important role in 
embryogenesis and tissue remodeling. Sox11 expression in most tissues is transient and thus 
little SOX11 expression has been found in terminally differentiated adult tissues. The role of 
SOX11 in the tumor microenvironment is cancer type-dependent.
SOX Genes and Cancer
http://dx.doi.org/10.5772/intechopen.72433
313
Our recent studies have demonstrated that SOX11 plays a tumor promotion role in the devel-
opment of head and neck cancer (HNC) [83]. We have employed a liquid chromatography–
tandem mass spectrometry (LC–MS/MS) based approach to identify novel targets that may 
interact with SOX11 in HNC cells. The proteins that strongly bind to SOX11 in HNC cells 
may be important for maintaining the activity, stability and function of SOX11 or be regu-
lated by SOX11. Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway analysis indicated that many potential SOX11-binding partners were associated 
with protein synthesis, cell metabolism and cell–cell adhesion. We speculated that upregula-
tion of SOX11 might firstly activate the aggressive phenotypes of HNC cells by modulating 
the oncoprotein synthesis and altering cellular metabolism. Then it might further promote 
invasion and metastasis by affecting cell–cell adhesion system and formation and release of 
extracellular exosomes. One of the identified proteins, heat shock protein 90 alpha (HSP90α), 
was selected for further investigation. A biochemical interaction is validated between SOX11 
and HSP90α through the co-immunoprecipitation with Western blot analysis. In addition, we 
have found that downregulation of HSP90α inhibits the malignant phenotypes of HNC cells 
and HSP90α upregulation is significantly associated with worse clinical outcome of HNC, 
suggesting HSP90α might serve as a potential prognostic biomarker and therapeutic target 
for HNC [84].
Aberrant expression of SOX11 has been reported in other types of cancer. SOX11 levels were 
negatively correlated with the tumorigenic capacity of glioma-initiating cells [85]. Similarly, 
epithelial ovarian cancer patients with lower SOX11 suffered poorer recurrence-free survival 
[55]. SOX11 mRNA was downregulated in both gastric cancer (GC) cell lines and primary 
GC tissues. SOX11 gene promoter hyper-methylation was significantly associated with worse 
clinical parameters and poorer prognosis, suggesting that SOX11 might function as a tumor 
suppressor in gastric cancer [86]. The methylation frequency of serum SOX11 promoter in 
hepatocellular carcinoma (HCC) patients was significantly higher than that in chronic hepa-
titis B (CHB) patients. In addition, significant difference of serum SOX11 promoter methyla-
tion in HCC patients with vascular invasion and those without vascular invasion was found. 
Moreover, serum SOX11 promoter methylation was found to be more sensitive than serum 
alpha-fetoprotein for discriminating HCC from CHB [87]. Previous studies also reported 
SOX11 functions an oncogene during tumorigenesis. SOX11 upregulation can promote onco-
genic behaviors of ductal carcinoma in situ (DCIS) cells both in vitro and in vivo, indicating 
that SOX11 contributes to the progression of ductal carcinoma in situ to invasive breast cancer 
[88]. Similarly, SOX11 is an important regulator of multiple basal-like breast cancers (BLBCs) 
phenotypes, including growth, migration, invasion, and expression of signature BLBC genes. 
In addition, high SOX11 expression was also found to be a poor prognostic indicator of sur-
vival in women with breast cancer [51].
SOX11 is expressed in virtually all aggressive mantle cell lymphoma (MCL) and at lower 
levels in a subgroup of Burkitt and acute lymphoblastic lymphomas, but not in other lym-
phoid neoplasms. The in vivo tumorigenic potential of SOX11 in a MCL xenograft model has 
been demonstrated, indicating that SOX11 functions as an oncogene in MCL [52]. In addi-
tion, SOX11 can block the terminal B-cell differentiation through direct positive regulation of 
PAX5 and promote angiogenesis in MCL through regulating platelet-derived growth factor 
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A [52, 53]. Patients with SOX11-negative MCL exhibited more frequent non-nodal presenta-
tion and better survival compared with patients with SOX11-positive MCL [54]. However, 
there is contradictory result bout the association between SOX11 and survival in MCL. The 
overall survival was shorter in patients with SOX11-negative MCL compared to the patients 
with SOX11-positive MCL [89]. The relationship between SOX11 expression and survival of 
patients with MCL remains uncertain.
7. Conclusion
In conclusion, recent studies have started to uncover important functions of the SOX genes as 
regulators of cancer initiation and progression. Our understanding of the role of SOX genes is, 
however, still at its infancy. Contradicting results regarding the role of SOX genes have been 
reported in different types of cancer. This suggests that the molecular functions of SOX genes 
in tumorigenesis need to be examined carefully in tissue-specific setting.
Abbreviation list
SOX sex determining region Y box
HMG high mobility group
MCL mantle cell lymphoma
HNC head and neck cancer
EMT epithelial-mesenchymal transition
TF transcription factor
HSP90α heat shock protein 90 alpha
KEGG Kyoto Encyclopedia of Genes and Genomes
LC–MS/MS liquid chromatography–tandem mass spectrometry
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